Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
Natera launched an enhanced version of its Panorama NIPT test, powered by novel SNP-informed deep sequencing technology. The update is backed by a prospective clinical validation study of 3,323 patients, demonstrating 100% sensitivity for trisomy 21 and 13, and 93.3% for trisomy 18 in low fetal fraction samples.
Key figures
- Study size
- 3323
- No call rate
- 0.5%
- Trisomy 13 sensitivity
- 100%
- Trisomy 18 sensitivity
- 93.3%
- Trisomy 21 sensitivity
- 100%
- Low fetal fraction samples
- 242
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.